EGFR and lung adenocarcinoma: Immune checkpoint inhibitors (ICI) as monotherapy result in disappointing outcomes in patients with EGFR-mutated lung adenocarcinoma, with low responses rates and low survival and should only be considered after exhaustion of other systemic therapies [7].